Abstracts tagged "Disability"

Abstract Number: 2302 • 2017 ACR/ARHP Annual Meeting
The Impact of JIA on Physician and Patient-Reported Outcomes over the First Five Years Following Diagnosis
Stephanie Shoop-Worrall¹, Suzanne M Verstappen², Janet E. McDonagh³, Wendy Thomson⁴ and Kimme L. Hyrich⁴, ¹The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal and Dermatology Research, Faculty of Medicine, Biology and Health, United Kingdom, University of Manchester, Manchester, United Kingdom, ³Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, ⁴National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Information regarding longer-term outcomes in JIA largely pre-date the introduction of biologic therapies and have been cross-sectional. The aim of this analysis was to…
Abstract Number: 2377 • 2017 ACR/ARHP Annual Meeting
Impact of Body Mass Index and Weight Loss on Incident Disability in Patients with Rheumatoid Arthritis
Joshua Baker¹, Ted R. Mikuls², Bryant R. England³, Michael D. George⁴, Grant Cannon⁵, Harlan Sayles⁶, Brian Sauer⁵, Liron Caplan⁷ and Kaleb Michaud⁶, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Obese patients with rheumatoid arthritis (RA) have greater disability in cross-sectional studies. There are no long-term studies that assess trajectories of disability among individuals…
Abstract Number: 2504 • 2017 ACR/ARHP Annual Meeting
The Validation of Istanbul Back Disability Index (IBDI) in Axial Spondyloarthritis Patients
Tuncay Duruoz, Hatice Sule Baklacioglu, Sevtap Acer Kasman and Didem Erdem, PMR Department, Rheumatology Division, Marmara University School of Medicine, Istanbul, Turkey
Background/Purpose: The IBDI was developed to assess the disability in patients with mechanical low back pain (1) which contains the 18 daily activities questions. The…
Abstract Number: 2208 • 2016 ACR/ARHP Annual Meeting
Mediators of the Relationship Between Pain and Disability in the Distal Upper Limb
Daniel Whibley^1,2,3, Kathryn Remmes Martin^1,2,3, Karina Lovell⁴, Gareth T. Jones^1,2,3 and Arm Pain Trial Investigators, ¹Arthritis Research UK / MRC Centre for Musculoskeletal Health and Work, University of Aberdeen, Aberdeen, United Kingdom, ²Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, United Kingdom, ³Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom, ⁴School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, United Kingdom
Background/Purpose: Disabling distal upper limb pain is common but relatively understudied. Fear avoidance (FA) models of disability have been empirically tested for back and lower…
Abstract Number: 2218 • 2016 ACR/ARHP Annual Meeting
Do Some Patients with Distal Upper Limb Pain Benefit More Than Others from Advice to Remain Active?
Daniel Whibley^1,2,3, Kathryn Remmes Martin^1,2,3, Karina Lovell⁴, Gary J. Macfarlane^1,2,3, Keith Palmer^5,6, David Coggon^5,6, Karen Walker-Bone^5,6, Kim Burton⁷, Peter Heine⁸, Candida McCabe^9,10, Paul McNamee¹¹, Alex McConnachie¹² and Gareth T. Jones^1,2,3, ¹Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, United Kingdom, ²Arthritis Research UK / MRC Centre for Musculoskeletal Health and Work, University of Aberdeen, Aberdeen, United Kingdom, ³Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom, ⁴School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, United Kingdom, ⁵MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁶University of Southampton, Arthritis Research UK / MRC Centre for Musculoskeletal Health and Work, Southampton, United Kingdom, ⁷Centre for Health and Social Care Research, University of Huddersfield, Huddersfield, United Kingdom, ⁸Warwick Clinical Trials Unit, University of Warwick, Coventry, United Kingdom, ⁹University of West of England, Bristol, Bristol, United Kingdom, ¹⁰Royal United Hospitals NHS Foundation Trust, Bath, United Kingdom, ¹¹Health Economics Research Unit, University of Aberdeen, Aberdeen, United Kingdom, ¹²Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: We have previously shown that, among patients awaiting physiotherapy for distal upper limb pain/disability, advice to remain active is associated with greater functional recovery…
Abstract Number: 2540 • 2016 ACR/ARHP Annual Meeting
The Longitudinal Impact of Biologic Use on Disability within a RA Registry
N A Shadick¹, Nicole Gerlanc², M Frits¹, Bradley S. Stolshek³, Brenna Brady², Christine Iannaccone⁴, David Collier⁵, Jing Cui⁶, Alex Mutebi⁷ and Michael Weinblatt⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Health Analytics, LLC, Columbia, MD, ³Amgen, Thousand Oaks, CA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Global Health Economics, Amgen, Thousand Oaks, CA
Background/Purpose: Biologics have become the standard of care for treating moderate to severe rheumatoid arthritis (RA) in patients with an inadequate response to small molecule…
Abstract Number: 2922 • 2016 ACR/ARHP Annual Meeting
Disability, Fatigue, and Their Associates in Early Diffuse Cutaneous Systemic Sclerosis
Ariane L. Herrick¹, Sébastien Peytrignet², Xiaoyan Pan³, Roger Hesselstrand⁴, Luc Mouthon⁵, László Czirják⁶, Madelon C. Vonk⁷, Oliver Distler⁸, Joerg H.W Distler⁹, Edith Brown³, Kim Fligelstone³, Rachel Ochiel¹⁰, William Gregory¹¹, Alan Silman¹², Mark Lunt¹³ and Christopher Denton¹⁴, ¹Centre for Musculoskeletal Research, University of Manchester, MAHSC, Salford Royal Hospital, Manchester, United Kingdom, ²Manchester Academic Health Sciences Centre, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Manchester Academic Health Science Centre, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁴Department of Rheumatology, Lund University, Lund, Sweden, ⁵Internal Medicine, Hopital Cochin, Paris, France, ⁶Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, ⁷Department of the Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁸Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁹Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, ¹⁰Royal Free London NHS Foundation Trust, London, United Kingdom, ¹¹Rehabilitation Services, Salford Royal NHS Foundation Trust, Salford, United Kingdom, ¹²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ¹³Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ¹⁴Centre for Rheumatology, Royal Free Hospital, London, Great Britain
Background/Purpose: ESOS (European Scleroderma Observational Study) was a prospective observational study of 326 patients with early diffuse cutaneous systemic sclerosis (dcSSc) from 50 centres. Here…
Abstract Number: 25 • 2016 ACR/ARHP Annual Meeting
Have Outcomes of Patients with Inflammatory Arthritis Improved in the New Millennium? a Comparison of the 10 Year Outcome in Cohorts Recruited in 1990-4 and 2000-4
James Gwinnutt¹, Deborah P.M. Symmons^1,2, Alex J Macgregor^3,4, Jacqueline Chipping^3,4, Tarnya Marshall^3,4, Mark Lunt¹ and Suzanne M.M. Verstappen¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ³Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ⁴School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, United Kingdom
Background/Purpose: New treatments have improved the short term outlook for patients with inflammatory polyarthritis (IP) over the past 20 years. However there is limited evidence…
Abstract Number: 116 • 2016 ACR/ARHP Annual Meeting
Racial Differences in Self-Reported Pain and Disability: A Longitudinal Study of Knee Osteoarthritis
Ernest Vina¹, Di Ran², Erin Ashbeck² and C. Kent Kwoh³, ¹Rheumatology, University of Arizona, Tucson, AZ, ²University of Arizona, Tucson, AZ, ³Rheumatology, University of Arizona, College of Medicine, Tucson, AZ
Background/Purpose: Pain and disability from knee osteoarthritis (KOA) has been reported to be greater among African-Americans (AAs) than Whites (WHs), though progression in KOA-related…
Abstract Number: 377 • 2016 ACR/ARHP Annual Meeting
Pain and Quality of Life Profiles in Colombian Patients with Rheumatoid Arthritis: A Mixed Cluster Analysis
Juan Manuel Cotte¹, Nicolás Molano-González², Deisy Hernández-Parra³, Yenifer Delgado-Scarpetta³, Adriana Rojas-Villarraga², Juan-Manuel Anaya¹ and Ricardo Pineda-Tamayo³, ¹Center for Autoimmune Diseases Research (CREA). School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bogotá, Colombia, ²Center for Autoimmune Diseases Research (CREA). School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bogotá D.C., Colombia, ³Artmédica IPS, Medellin, Colombia, Medellin, Colombia
ABSTRACT Background/Purpose: Among the symptoms of Rheumatoid Arthritis (RA), pain is often regarded as a critical factor related to quality of life (QoL) by patients,…
Abstract Number: 395 • 2016 ACR/ARHP Annual Meeting
The Influence of Early Achievement of “Clinically Inactive Disease” or “Minimal Disease Activity” on Long-Term Disability Outcomes in JIA
Stephanie J.W.Shoop^1,2, Suzanne M.M. Verstappen³, Janet E. McDonagh⁴, Wendy Thomson^5,6, Kimme L. Hyrich^3,7 and CAPS, ¹Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ²The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Different definitions of clinically inactive disease (CID) for JIA have recently been shown to identify different groups of children. It is unclear whether long-term…
Abstract Number: 407 • 2016 ACR/ARHP Annual Meeting
Comparability of Proxy, Adolescent and Adult Measures of Functional Ability in Adolescents with JIA
Stephanie J.W.Shoop^1,2, Kimme L. Hyrich^3,4, Suzanne M.M. Verstappen⁴, Wendy Thomson^5,6, Janet E. McDonagh⁷ and CAPS, ¹The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ³Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom
Background/Purpose: It is unclear which tool should measure functional ability in adolescents with JIA. The proxy-completed Childhood Health Assessment Questionnaire (P-CHAQ) is completed on the…
Abstract Number: 537 • 2016 ACR/ARHP Annual Meeting
Differences and Associated Factors in General Disability and Hand Disability Between Patients with Rheumatoid Arthritis and Psoriatic Arthritis
Jose Andres Roman Ivorra¹, Óscar Álvarez¹, Jose Ivorra Cortes¹, Javier Navarro Muñoz², Elena Grau Garcia³, Luis Gonzalez Puig¹, Inmaculada Chalmeta Verdejo¹, Carlos Feced Olmos¹, Eztizen Labrador Sanchez¹, Francisco Miguel Ortiz-Sanjuán⁴, Karla Arevalo Ruales¹, Rosa Negueroles Albuixech¹, Jorge Fragio Gil¹, Isabel Martinez Cordellat¹, Jose Luis Valero Sanz¹, Cristina Alcañiz Escandell^1,3, Gema Poveda Marin^1,3, Carmen Najera Herranz¹ and Victoria Fornes Ferrer⁵, ¹Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Universidad Católica de Valencia, Valencia, Spain, ³IIS La Fe, Valencia, Spain, ⁴Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Santander, Spain, ⁵Biostatistics Unit. IIS La Fe, Valencia, Spain
Background/Purpose: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are well-known disabling conditions, with high impact on patients functioning and quality of life. However, little is…
Abstract Number: 550 • 2016 ACR/ARHP Annual Meeting
Despite Early Improvement and Limited Self-Reported Disability, Patients with Rheumatoid Arthritis Still Have Impaired Grip Strength 5 Years after Diagnosis
Maria Rydholm^1,2, Christina Book^1,2, Ingegerd Wikström^1,2, Lennart T.H. Jacobsson^1,3 and Carl Turesson^1,2, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ³Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden
Background/Purpose: Methods: An inception cohort of patients with Grip force (Newton, N) was measured using the electronic instrument Grippit (AB Detektor, Gothenburg, Sweden). Average…
Abstract Number: 552 • 2016 ACR/ARHP Annual Meeting
Disability in Early Rheumatoid Arthritis, Course and Predictors
Therese Hansson^1,2, Christina Book^1,2, Lennart T.H. Jacobsson^1,3 and Carl Turesson^1,2, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ³Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden
Background/Purpose: Patient reported outcome measures (PROMs), including the Health Assessment Questionnaire Disability Index (HAQ-DI), are valuable and reliable instruments for assessment of disease severity and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.